In short
A new clinical trial is underway to assess the effectiveness and safety of Gemlapodect (also known as NOE-105) in treating Tourette Syndrome. This study focuses on reducing tics in both adults and adolescents with this condition. Gemlapodect is a selective PDE10A inhibitor, which means it targets a specific enzyme in the brain that may help control tic symptoms. The trial will compare Gemlapodect to a placebo over a 12-week period to determine its potential as a new treatment option for Tourette Syndrome.
At a glance
- Drug Name
- Gemlapodect (NOE-105)
- Condition Studied
- Tourette Syndrome
- Study Type
- Phase 2b, double-blind, placebo-controlled
- Duration
- 12 weeks
- Participants
- Adults and adolescents with Tourette Syndrome
- Primary Outcome Measure
- Change in tic severity (YGTSS-R score)
- Secondary Outcome Measures
- Patient functioning, premonitory urge for tics, safety and tolerability, suicidality assessment
- Administration
- Oral capsules, once daily
What is Gemlapodect?
Gemlapodect, also known as NOE-105, is an investigational drug being studied for the treatment of Tourette Syndrome (TS). Tourette Syndrome is a neurological disorder characterized by repetitive, involuntary movements and vocalizations called tics. Gemlapodect is specifically designed to help reduce the tics associated with this condition.
How Does Gemlapodect Work?
Gemlapodect is classified as a selective PDE10A inhibitor. While the exact mechanism may be complex, in simple terms, this means that the drug targets a specific enzyme in the brain called PDE10A. By inhibiting this enzyme, Gemlapodect may help to regulate brain activity in ways that could reduce the frequency and severity of tics in people with Tourette Syndrome.
Clinical Trial Overview
A clinical trial is currently underway to evaluate the effectiveness and safety of Gemlapodect. Here are the key points about this study:
- Study Type: This is a Phase 2b clinical trial, which means it's testing the drug in a larger group of people to further assess its effectiveness and safety.
- Participants: The study includes both adults and adolescents with Tourette Syndrome. However, adolescents will only be enrolled after a initial group of adults completes the study.
- Duration: The treatment period lasts for 12 weeks (about 3 months).
- Study Design: This is a "double-blind, placebo-controlled" study. This means that some participants will receive Gemlapodect, while others will receive a placebo (a harmless substance with no active ingredients). Neither the participants nor the researchers will know who is receiving which treatment until the study is complete.
Efficacy Measurements
The main goal of this study is to determine how well Gemlapodect works in reducing tics. The researchers will measure this using several methods:
- Yale Global Tic Severity Scale (YGTSS-R): This is the primary tool used to measure the effectiveness of Gemlapodect. It's a scoring system that evaluates the number, frequency, intensity, complexity, and interference of both motor and vocal tics. The scores range from 0 to 50, with higher scores indicating more severe tics.
- Premonitory Urge for Tics Scale: This scale measures the intensity of the urges that often precede tics in people with Tourette Syndrome.
Safety and Side Effects
As with any new medication, it's crucial to assess the safety of Gemlapodect. The study will closely monitor:
- Adverse Events: Any unexpected medical occurrences in participants during the study will be recorded and analyzed. This includes both mild side effects and more serious health issues.
- Suicidality Assessment: The researchers will use a tool called the Columbia Suicide Severity Rating Scale (C-SSRS) to monitor any changes in suicidal thoughts or behaviors among participants.
Patient Impact
Beyond just reducing tics, the researchers are interested in how Gemlapodect might improve overall quality of life for people with Tourette Syndrome. They will assess this using:
- Sheehan Disability Scale: This tool measures how much a person's symptoms interfere with their work/school, social life, and family life/home responsibilities.
It's important to note that while Gemlapodect shows promise, it is still in the testing phase. More research is needed before it can be approved for general use in treating Tourette Syndrome. If you have Tourette Syndrome and are interested in participating in clinical trials, it's best to discuss this with your healthcare provider.